About RxRevu
RxRevu is a private company based in Denver, Colorado. It has reported $22,552,107 raised in four offerings on Form D since April 2014. Its chief executive is Kyle Kiser.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 30, 2022 | Jan 17, 2023 | $6,000,000of $10.0M target | 1 | $6.0M | EquityRule 506(b) | Form D ↗ |
| Jun 21, 2021 | Jul 8, 2021 | $8,000,000fully sold | 1 | $8.0M | EquityRule 506(b) | Form D ↗ |
| Dec 22, 2016 | Jan 6, 2017 | $4,737,107of $5.4M target | 44 | $107K | EquityRule 506(b) | Form D ↗ |
| Mar 14, 2014 | Apr 9, 2014amended Oct 28, 2016 | $3,815,000of $4.5M target | 44 | $86,705 | Convertible Promissory Notes and the equity securities issuable upon conversion of such notes.Rule 506(b) | Form D/A ↗2 earlier filings |
| Total, four offerings | $22,552,107 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on RxRevu's Form D filed Jan 17, 2023.
SM
Stephen McHale
Director
KK
Kyle Kiser
Chief Executive Officer and director
AF
Andrew Firlik
Director
SL
Steve Lindseth
Executive officer and director
CC
Christie Callahan
Executive officer
TC
Toby Cosgrove
Director
AP
Albert Prast
Director
BB
Benton Barney
Executive officer
RZ
Richard Zane
Director
AC
Aaron Cornell
Executive officer
DG
Daniel Galles
Director
LP
Lew Parker
Executive officer
Earlier filings also listed Kevin O'Brien (executive officer and director, last listed Jan 2017), Jeffrey Patton (director, last listed Jan 2017), David Huntress (president and chief executive officer, director, last listed Jan 2017) and Daniel Caron (executive officer, last listed Jan 2017).